Related Experiment Video
Updated: Jan 8, 2026

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
Published on: February 15, 2019
Genetic mutations, pathology, and single-nucleus transcriptomic landscape in LVHT patients reveal differential
Yifan Wang1, Weiteng Wang1, Han Mo1
1Beijing Key Laboratory of Preclinical Research & Evaluation for Cardiovascular Implant Materials, Animal Experimental Centre, National Centre for Cardiovascular Disease, Department of Cardiac Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Insights
Left ventricular hypertrabeculation/non-compaction (LVHT) progression to heart transplantation is linked to specific transcriptomic and pathological features. The Notch pathway molecule MAML3 may indicate disease advancement in LVHT patients.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Left ventricular hypertrabeculation/non-compaction (LVHT) presents unique cardiac morphology but variable clinical outcomes.
- Factors driving LVHT progression to heart transplantation are not well understood.
- No prior studies linked LVHT transcriptomic or pathological features to transplantation progression.
Purpose of the Study:
- To investigate the transcriptomic and pathological features of LVHT.
- To determine factors influencing LVHT progression to heart transplantation.
- To identify potential biomarkers for disease progression.
Main Methods:
- Whole-exome sequencing in 74 LVHT patients.
- Single-nucleus RNA sequencing on explanted LVHT hearts.
- Histopathological analysis of myocardial composition, fibrosis, and non-compaction.
Main Results:
- Genetic variants found in 46% of patients, not linked to transplantation.
- Transcriptional profiles of compacted and non-compacted LVHT layers were similar.
- Notch signaling was enriched; MAML3 upregulation correlated with faster progression to transplantation.
- Fibrosis and non-compaction distribution linked to cardiac function and transplant outcomes.
Conclusions:
- LVHT exhibits distinct transcriptomic and pathological features impacting heart transplantation progression rates.
- The Notch pathway molecule MAML3 shows potential as a marker for LVHT disease progression.
Background:
Left ventricular hypertrabeculation/non-compaction (LVHT/LVNC) is characterized by a thinned myocardial wall, prominent trabeculations, and deep intertrabecular recesses. It presents with unique cardiac morphology and hemodynamic features but displays considerable clinical heterogeneity. The factors influencing disease progression to heart transplantation remain unclear. No studies have investigated the relationship between transcriptomic or pathological features of LVHT and progression to transplantation.
Methods:
We enrolled 74 patients diagnosed with LVHT, among whom 63 underwent whole-exome sequencing to assess genetic variants. Explanted heart tissue was obtained from 24 patients who received heart transplantation, and single-nucleus RNA sequencing was performed on the compacted and non-compacted layers of the left ventricle in 3 LVHT patients, compared with 3 normal controls. In addition, myocardial composition, fibrosis, fat content, and the extent of non-compaction were evaluated histopathologically.
Results:
Genetic variants were detected in 46 % of patients but were not associated with progression to heart transplantation. The compacted and non-compacted layers of LVHT hearts exhibited highly similar transcriptional profiles. Notch signaling was enriched in LVHT-related cardiomyocyte clusters. MAML3, a Notch coactivator, was significantly upregulated in LVHT compared with other cardiomyopathies and normal myocardium, and was associated with faster progression to transplantation. Histopathological analysis further demonstrated that both myocardial fibrosis and the anatomical distribution of non-compaction were linked to cardiac function and transplant outcomes.
Conclusion:
LVHT is associated with distinct transcriptomic and pathological features that influence the rate of progression to heart transplantation. The Notch pathway-related molecule MAML3 may serve as a potential marker of disease progression in LVHT.
More Related Videos
08:38Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
Published on: July 21, 2023
10:03Author Spotlight: Nuclei Isolation from Mouse Cardiac Progenitor Cells for Epigenome and Gene Expression Profiling at Single-Cell Resolution
Published on: May 12, 2023
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure II: Pathophysiology
Cardiomyopathy V: Interprofessional Care